Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection

Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions

Vetter ramps up global clinical manufacturing push with major US & Europe expansion

The goal is to better support drug developers as programs move from laboratory research into clinical trials

NantBioRenewables expands US manufacturing footprint in Alabama

To boost compostable packaging, resin innovation, and supply chain speed

FDA clears Travere’s FILSPARI for expanded use in rare kidney disease

Avantor India expands strategic collaboration with Parafilm to strengthen access to lab consumables

Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing

FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access